ZL-2102

N/A

Report date: 2022/09/16 14:57:20
NME

Base Information

Drug NameZL-2102
Drug Alias NameZL-2102SAR-191801
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstaglandin-H2 D-isomerase inhibitors
TargetsProstaglandin-H2 D-isomerase
Therapy Area/IndicationsIdiopathic Pulmonary FibrosisPulmonary Disease, Chronic ObstructiveLung Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSanofi
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZai Lab Pty LtdZai Lab (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary FibrosisPulmonary Disease, Chronic ObstructiveLung Diseases +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A